
200 Front Street West, Suite 2800
Toronto, ON M5V 3L1
Tel: 416 205 1300 Fax: 416 205 1360
www.oha.com

June 5, 2009

**For the Attention of
Hospital CEOs, OHA Board of Directors, Infection Prevention
and Control Leads, Occupational Health and Safety leads,
Joint Health and Safety Committee, CACN, Chief HR Officers,
Emergency Department Managers, Emergency Preparedness
and Pandemic Planning Leads**

**From: Greg Shaw, Vice President,
Strategic Human Resources Management Services**

Update: H1N1 Influenza A

The Ministry of Health and Long-Term Care (MOHLTC) has issued an Important Health Notice (IHN) and two new sets of guidelines – one for ambulatory settings and another for emergency departments.

Some highlights from the IHN and the new guidelines:

- H1N1 influenza A virus is the predominant circulating strain of influenza in many communities at this time
- For Ambulatory Care Settings and Emergency Departments, laboratory testing is only required for clinical management of hospitalized cases of influenza-like illness (ILI) or for patients at high risk for complication
- Individuals who meet the symptom criteria for ILI should self-isolate and not present to their work setting. The length of time the individual should remain off work will depend on their work setting.

For more information, contact Tim Savage, Health and Safety Consultant at 416-205-1395 (tsavage@oha.com). A complete list of OHA updates and hospital support materials is available at www.oha.com/h1n1influenzaA.

Ministry of Health and Long-Term Care

Guidance for Management of Patients with Influenza-like Illness (ILI) in Ambulatory Settings

Please refer to Important Health Notice Volume 6, Issue 13 issued on June 4, 2009

What's Changed:

June 4, 2009

- Laboratory testing recommendations (see page 3) have been revised:
 - Laboratory testing for patients with mild symptoms of ILI is not currently recommended
 - Laboratory testing related to clinical management should only be performed on patients requiring hospitalization and on patients at high risk for complications from influenza (e.g., immunocompromised, pregnant, persons under the age of 2 years and over 65 years of age)

Information as of June 4, 2009 indicates that the current novel H1N1 influenza virus has characteristics similar to seasonal influenza¹ (clinical features, morbidity and mortality, epidemiology). However, because it is a novel virus with pandemic potential, these guidelines are precautionary and will be updated as new information and evidence becomes available.

Ambulatory settings may include, but are not limited to, physician offices and clinics, diagnostic imaging, and lab collection services, and allied health professional services.

The number of novel H1N1 influenza A cases acquired in Ontario has been increasing as the virus spreads in the general population, much as seasonal influenza does.

The presence of the virus in the community and associated transmission from person-to-person suggests that H1N1 should be assumed to be the

¹ Influenza is predominantly a droplet-borne disease; however, transmission via small airborne sized particles cannot be ruled out. Influenza virus can also survive on surfaces therefore, both droplet and contact precautions are recommended to prevent transmission.

predominant circulating strains of influenza at this time.

This document has been issued to update the previous information provided and should be used as the most current guidance for the management of ILI in the clinical setting.

1. Background

The Ontario Health Plan for an Influenza Pandemic (OHPIP) advises that it is prudent to wear fit-tested N95 respirators when within 2 metres of caring for a patient with an influenza virus of pandemic potential. Since travel history can no longer accurately predict who is infected with the novel H1N1 strain, it follows that a fit-tested N95 respirator in addition to droplet and contact precautions should be used by healthcare workers when within 2 metres of caring for all patients with influenza-like illness (ILI).

The recommendations outlined in this document are based upon implementation of the broadest level of precautionary measures. Where supplies of N95 respirators and other personal protective equipment (PPE) are limited or depleted, N95 respirator and PPE use by health care workers should be prioritized as recommended in chapter 7 of the OHPIP

(www.health.gov.on.ca/english/providers/program/emu/pan_flu/ohpip2/ch_07.pdf). If an N95 respirator is not available, healthcare workers are advised to don a surgical mask wherever an N95 respirator is called for in this document and, if possible, to put a surgical mask on their patient.

Individuals who meet the symptom criteria for ILI should self-isolate and not present to their work setting. The length of time the individual should remain off work will depend on their work setting (see Patient Disposition and Treatment for advice in the non-healthcare and healthcare settings).

General information on infection prevention and control practices in ambulatory settings can be found by visiting the College of Physicians and Surgeons of Ontario website at:

www.cpso.on.ca/uploadedFiles/policies/guidelines/office/Infection_Controlv2.pdf

2. Screening

Passive: All settings should have signage posted requesting any patient with a new/worsening cough or respiratory illness to perform hand hygiene and don a surgical mask.

Sample signage is available at:

www.health.gov.on.ca/english/public/updates/archives/hu_09/provider/default.html

Active: Patients should also be actively triaged/screened using the ‘Screening Tool for Influenza-like Illness (ILI)’ (available at: www.health.gov.on.ca/english/public/updates/archives/hu_09/provider/default.html). Where applicable, these screening questions should be asked at the time the patient telephones to book an appointment. The patient can then be informed of the need to don a mask immediately upon arrival to the office. Masks and alcohol-based hand rub should be available at all entrances.

3. Patient Management

All patients who present with ILI (see definition below) should be managed as follows:

- Physical barrier (i.e., window or plexiglass barrier) or the receptionist should maintain a 2 metre distance from all patients whenever

possible². In settings where such a separation is not possible, health care workers are advised to maintain whatever separation is feasible.

- If there is no barrier, and a 2 metre distance cannot be achieved, a fit-tested N95 respirator and eye protection should be worn by the receptionist
- Alcohol-based hand rub (ABHR) should be readily available for both staff and patients
- Patient should be asked to perform hand hygiene using an ABHR and given a surgical mask to put on covering their nose and mouth
- Patient should be placed in a separate area of the office (i.e., examination room) and continue to wear the mask to decrease the environmental contamination. If an examination room or separate room is not available, the patient should remain masked and be placed as far from other patients as possible.

Routine Practices should be used consistently with all patients including:

- Hand hygiene before and after all patient contact
- Appropriate use of personal protective equipment (e.g., gloves, gowns, eye protection) for contact with all patient secretions/excretions as per Routine Practices (see CPSO link above)
- Appropriate disinfection of all equipment which is shared between patients
- Cleaning/disinfection of all patient contact surfaces after patient leaves the examining room

Definition of Influenza-like Illness (ILI)

Acute onset of respiratory illness with fever and cough and with one or more of the following: sore throat, arthralgia, myalgia, or prostration, which could be due to influenza virus. In children under 5 years of age, gastrointestinal symptoms may also be present. In patients under 5 years of age or 65 years and older, fever may not be prominent.

Infection Prevention and Control for Health Care Workers

Health care workers providing direct care to patients with ILI should use the following precautions in addition to Routine Practices.

² This is a precautionary measure as the incremental benefit of maintaining a 2 metre separation from influenza patients is unknown.

- Hand hygiene (alcohol-based hand rub or soap and running water)
- Eye protection
- Gown and gloves if there is a risk of widespread contamination with respiratory secretions
- Fit-tested N95 respirator

After the patient leaves the examining area, surfaces which may have been touched by the patient (e.g., stretcher, counters, overbed tables, etc.) and been contaminated with droplets must be cleaned with a hospital-grade disinfectant.

4. Laboratory Testing (Updated June 4th)

Testing for novel H1N1 Influenza A is not recommended for patients with mild disease.

Testing related to clinical management of patients with ILI should only be performed on patients requiring hospitalization and on patients at high risk for complications from influenza (e.g., immunocompromised, pregnant, persons under the age of 2 years and over 65 years of age).

Treatment with antivirals should be based on clinical features and risk assessment only (see Section 6, below).

The rationale for this change is as follows:

- H1N1 has been confirmed as the predominant circulating influenza strain in many communities and there is little utility for routine testing once the virus is widespread in the community.
- The diagnosis of an influenza-like illness can be made on a clinical basis and testing does not alter treatment recommendations.

If a nasopharyngeal (NP) swab is obtained, clinical symptoms and risk factors must be written on the laboratory requisition and the specimen should be forwarded following the usual protocols for submission of laboratory specimens to the local community or hospital laboratory.

Specimens may be forwarded by the local community or hospital laboratory, if testing is not available or if specimen requires further testing, to the nearest Public Health Laboratory. Specimens forwarded by hospital laboratory for further confirmation is at the discretion of the hospital laboratory director.

Specimens

- Nasopharyngeal swab in viral transport media

It is critical that clinical symptoms and risk factors be written on the test requisition in order to triage specimens. Specimens from asymptomatic patients will not be tested.

Transportation of Specimens

- Transport specimens to the laboratory at 4°C
- For critically ill patients, please phone 1-800-640-7221, or after hours 416-605-3113.

If additional NP swabs and transport media required; please fill out a Supply Requisition Form and send to your local public health laboratory.

To access the Supply Requisition Form go to www.oahpp.ca/SRI%20Bulletin.php and click on the document: Requisition for Specimen Containers and Supplies – August 2007.

5. Patient Reporting

There is no requirement for reporting cases of ILI to your local public health unit beyond that which is usually required for seasonal influenza. As a reminder, patients who have laboratory confirmed influenza or those who are part of an unusual cluster must be reported promptly to your local public health unit. Institutional outbreaks of respiratory infections are reportable as usual.

6. Patient Disposition and Treatment

Patients who do not require admission to a health care facility should be provided with education to assist in containing the spread of their illness to others. This education should include information on:

- Hand hygiene
- Respiratory cough etiquette
- Social distancing (i.e., minimizing contact with family members, not going out in public while symptomatic)
- Absence from their workplace is dependent on the work setting. In general:

- *Patients working in a non-healthcare setting should remain off work until they are afebrile and feeling better.*
- *Patients who work in a healthcare setting should remain off work until 7 days after the onset of their symptoms and they are afebrile and feeling better.*

NOTE: It is not unusual for individuals to experience a cough for days to weeks post infection. Presence of a cough in the absence of other symptoms is not sufficient to keep an employee away from the work setting.

Individuals who work in health care settings are less likely to be able to practice social distancing during the course of their work. In addition, they may be providing close care to patients who may be at higher risk of complications should they become ill.

Treatment Recommendations

Treatment of the following groups with ILI with oseltamivir is currently recommended within 48 hours of the onset of symptoms:

- Fever and acute ILI or pneumonia requiring hospitalization
- ILI and at risk for complicated disease

Other patients with ILI do not require treatment.

Comment on the Treatment of Children and Pregnant Women

Oseltamivir and zanamivir are ‘Pregnancy Category C’ medications, indicating that no clinical studies have been conducted in humans to assess the safety of these medications for pregnant women. The National Advisory Committee on Immunization has stated that in ‘healthy pregnant women the risk of influenza-related hospitalization increases with increasing length of gestation; e.g. it is higher in the 3rd than the 2nd trimester.’ In making treatment decisions, the 3rd trimester more than the 2nd trimester should be considered a risk factor for more severe influenza whereas first trimester pregnancy should not be considered a risk factor for severe disease.

On May 12, 2009, the Centers for Disease Control and Prevention (CDC) published recommendations

for the treatment of pregnant women. These recommendations are available at: www.cdc.gov/mmwr/pdf/wk/mm58d0512.pdf There are no corresponding Public Health Agency of Canada recommendations at this point in time. Clinicians must make treatment decisions in collaboration with their patient considering the best available information, authoritative guidelines and the clinical presentation of the patient. Any decision related to the treatment of a pregnant woman should be made between the clinician and patient after careful discussion of the risks and benefits of the proposed treatment.

The use of oseltamivir in children under the age of 1 year has been studied in a very limited number of children. CDC has recently received emergency approval in the United States for use in infants under 1 year of age with suggested dosing guidelines. The use of zanamivir in children under the age of 7 is not well studied and it is technically difficult to administer.

The Canadian Paediatric Society has recommended that the use of antivirals in children be confined to:

- Children hospitalized with H1N1 influenza virus
- Outpatient children with moderate illness and specified underlying chronic health conditions.

Details regarding the treatment of children are available at: www.cps.ca/english/statements/ID/H1N1Mexico2009.htm

Ministry of Health and Long-Term Care

Guidance for Management of Patients with Influenza-like Illness (ILI) in Emergency Departments

Please refer to Important Health Notice Volume 6, Issue 13 issued on June 4, 2009

What's Changed:

June 4, 2009

- Laboratory testing recommendations (page 2) have been revised:
 - Laboratory testing for patients with mild symptoms of ILI is not currently recommended
 - Laboratory testing related to clinical management should only be performed on patients requiring hospitalization and on patients at high risk for complications from influenza (e.g., immunocompromised, pregnant, persons under the age of 2 years and over 65 years of age)

Information as of June 4, 2009 indicates that the current novel H1N1 influenza virus has characteristics similar to seasonal influenza¹ (clinical features, morbidity and mortality, epidemiology). However, because it is a novel virus with pandemic potential, these guidelines are precautionary and will be updated as new information and evidence becomes available.

The number of novel H1N1 influenza A cases acquired in Ontario has been increasing as the virus spreads in the general population, much as seasonal influenza does.

The presence of the virus in the community and associated transmission from person-to-person suggests that H1N1 should be assumed to be the predominant circulating strain of influenza at this time.

This document has been issued to update the previous information provided and should be used as

¹ Influenza is predominantly a droplet-borne disease; however, transmission via small airborne sized particles cannot be ruled out. Influenza virus can also survive on surfaces therefore, both droplet and contact precautions are recommended to prevent transmission.

the most current guidance for the management of ILI in the clinical setting.

1. Background

The Ontario Health Plan for an Influenza Pandemic (OHPIP) advises that it is prudent to wear fit-tested N95 respirators when within 2 metres of caring for a patient with an influenza virus of pandemic potential. Since travel history can no longer accurately predict who is infected with the novel H1N1 strain, it follows that a fit-tested N95 respirator in addition to droplet and contact precautions should be used by healthcare workers when within 2 metres of caring for all patients with influenza-like illness (ILI).

The recommendations outlined in this document are based upon implementation of the broadest level of precautionary measures. Where supplies of N95 respirators and other personal protective equipment (PPE) are limited or depleted, N95 respirator and PPE use by healthcare workers should be prioritized as recommended in chapter 7 of the OHPIP (www.health.gov.on.ca/english/providers/program/emu/pan_flu/ohpip2/ch_07.pdf). If an N95 respirator is not available, health care workers are advised to don a surgical mask wherever an N95 respirator is

called for in this document and, if possible, to put a surgical mask on their patient.

Individuals who meet the symptom criteria for ILI should self-isolate and not present to their work setting. The length of time the individual should remain off work will depend on their work setting (see Patient Disposition and Treatment for advice in the non-healthcare and healthcare settings).

2. Screening

All patients presenting to the Emergency Department should be actively screened at the time of triage for respiratory illnesses using the 'Screening Tool for Influenza-like Illness' (available at:

www.health.gov.on.ca/english/public/updates/archives/hu_09/provider/default.html).

Passive surveillance (signage asking patients to self-report symptoms) should also be available at the point of entry to the department. Patients who present to triage with a new/worsening cough or respiratory illness should be asked to perform hand hygiene and don a surgical mask.

Triage staff should wear fit-tested N95 respirators and eye protection when conducting active surveillance of patients presenting with respiratory symptoms. Respirators and eye protection are not required for triage of patients without respiratory symptoms.

3. Patient Management

Patients will be managed based on symptoms and history of onset of symptoms. Patients with onset of symptoms within the previous 7 days or with acute clinical symptoms will be cared for using N95 respirators and eye protection in addition to Routine Practices.

Definition of Influenza-like Illness (ILI)

Acute onset of respiratory illness with fever and cough and with one or more of the following: sore throat, arthralgia, myalgia, or prostration, which could be due to influenza virus. In children under 5 years of age, gastrointestinal symptoms may also be present. In patients under 5 years of age or 65 years and older, fever may not be prominent.

Infection Prevention and Control for Health Care Workers

Health care workers providing direct care to patients with ILI should use the following precautions in addition to Routine Practices.

- Hand hygiene (alcohol-based hand rub or soap and running water)
- Eye protection
- Gown and gloves if there is a risk of widespread contamination with respiratory secretions
- Fit-tested N95 respirator

After the patient leaves the examining area, surfaces which may have been touched by the patient (e.g., stretcher, counters, overbed tables, etc.) and been contaminated with droplets must be cleaned with a hospital-grade disinfectant.

4. Laboratory Testing (Updated June 4th)

Testing for novel H1N1 Influenza A is not recommended for patients with mild disease.

Testing related to clinical management of patients with ILI should only be performed on patients requiring hospitalization and on patients at high risk for complications from influenza (e.g., immunocompromised, pregnant, persons under the age of 2 years and over 65 years of age).

Treatment with antivirals should be based on clinical features and risk assessment only (see Section 6, below).

The rationale for this change is as follows:

- H1N1 has been confirmed as the predominant circulating influenza strain in many communities and there is little utility for routine testing once the virus is widespread in the community.
- The diagnosis of an influenza-like illness can be made on a clinical basis and testing does not alter treatment recommendations.

If a nasopharyngeal (NP) swab is obtained, clinical symptoms and risk factors must be written on the laboratory requisition and the specimen should be forwarded following the usual protocols for submission of laboratory specimens to the local community or hospital laboratory.

Specimens may be forwarded by the local community or hospital laboratory, if testing is not available or if specimen requires further testing, to the nearest Public Health Laboratory. Specimens forwarded by hospital laboratory for further confirmation is at the discretion of the hospital laboratory director.

Specimens

Mandatory for patients with moderate to severe ILI

- Nasopharyngeal swab in viral transport media
- Blood in clotted tube (red top)
- Blood in EDTA (purple top)

It is critical that clinical symptoms and risk factors be written on the test requisition in order to triage specimens. Specimens from asymptomatic patients will not be tested.

5. Patient Reporting

There is no requirement for reporting cases of ILI to your local public health unit beyond that which is usually required for seasonal influenza. As a reminder, patients who have laboratory confirmed influenza or those who are part of an unusual cluster must be reported promptly to your local public health unit. Institutional outbreaks of respiratory infections are reportable as usual.

6. Patient Disposition and Treatment

a) Patients who are well enough to be discharged home should be instructed:

- To monitor for signs and symptoms and seek medical attention if symptoms worsen
- Absence from their workplace is dependent on the work setting. In general:
 - *Patients working in a non-healthcare setting should remain off work until they are afebrile and feeling better.*
 - *Patients who work in a healthcare setting should remain off work until 7 days after the onset of their symptoms and they are afebrile and feeling better.*

NOTE: It is not unusual for individuals to experience a cough for days to weeks post

infection. Presence of a cough in the absence of other symptoms is not sufficient to keep an employee away from the work setting.

Individuals who work in health care settings are less likely to be able to practice social distancing during the course of their work. In addition, they may be providing close care to patients who may be at higher risk of complications should they become ill.

Patients should be provided with education to assist in containing the spread of their illness to others. This education should include information on:

- Hand hygiene
- Respiratory cough etiquette
- Social distancing (i.e., minimizing contact with family members, not going out in public)
- Not going to work until acute symptoms have resolved

b) Patients with severe ILI requiring admission should be managed with:

- Single room
- Healthcare providers wearing fit-tested N95 respirators and eye protection when providing direct patient care and within 2 metres (6 foot) of the patient. In settings where such a separation is not possible, healthcare workers are advised to maintain whatever separation is feasible.²

Treatment Recommendations

Treatment of the following groups with ILI with oseltamivir is currently recommended within 48 hours of the onset of symptoms:

- Fever and acute ILI or pneumonia requiring hospitalization
- ILI and at risk for complicated disease

Other patients with ILI do not require treatment.

Comment on the Treatment of Children and Pregnant Women

² This is a precautionary measure as the incremental benefit of maintaining a 2 metre separation from influenza patients is unknown.

Oseltamivir and zanamivir are ‘Pregnancy Category C’ medications, indicating that no clinical studies have been conducted in humans to assess the safety of these medications for pregnant women. The National Advisory Committee on Immunization has stated that in ‘healthy pregnant women the risk of influenza-related hospitalization increases with increasing length of gestation; e.g. it is higher in the 3rd than the 2nd trimester.’ In making treatment decisions, the 3rd trimester more than the 2nd trimester should be considered a risk factor for more severe influenza whereas first trimester pregnancy should not be considered a risk factor for severe disease.

On May 12, 2009, the Centre for Disease Control and Prevention (CDC) published recommendations for the treatment of pregnant women. These recommendations are available at: www.cdc.gov/mmwr/pdf/wk/mm58d0512.pdf There are no corresponding Public Health Agency of Canada recommendations at this point in time. Clinicians must make treatment decisions in collaboration with their patient considering the best available information, authoritative guidelines and the clinical presentation of the patient. Any decision related to the treatment of a pregnant woman should be made between the clinician and patient after careful discussion of the risks and benefits of the proposed treatment.

The use of oseltamivir in children under the age of 1 year has been studied in a very limited number of children. CDC has recently received emergency approval in the United States for use in infants under 1 year of age with suggested dosing guidelines. The use of zanamivir in children under the age of 7 is not well studied and it is technically difficult to administer.

The Canadian Paediatric Society has recommended that the use of antivirals in children be confined to:

- Children hospitalized with H1N1 influenza virus
- Outpatient children with moderate illness and specified underlying chronic health conditions.

Details regarding the treatment of children are available at: www.cps.ca/english/statements/ID/H1N1Mexico2009.htm

Important Health Notice

June 4, 2009

Information for Healthcare Professionals UPDATE

Volume 6, Issue 13

Page 1 of 2

This Important Health Notice (IHN) is based on current information received to date and provides the following:

- Status update
- Revision to laboratory testing recommendations for Ambulatory Care Settings and Emergency Departments
- Hours of operation for the Health Care Provider Hotline

Status Update:

The World Health Organization pandemic threat level remains unchanged at Phase Five.

As of June 3, 2009 there were 969 lab-confirmed cases of novel H1N1 Influenza A virus in Ontario. Of these cases, 54 had a travel history to Mexico. Of the remaining 915 cases, 525 acquired the H1N1 flu virus in Ontario, 11 had a travel history to another affected region and 379 cases continue to be investigated. Nearly all H1N1 cases in Ontario are considered mild. There have been few hospitalized cases, most of whom have recovered and have been discharged.

Direction on Lab Testing:

The significant amount of laboratory testing conducted to date has shown that the 2009 novel H1N1 influenza A virus is the predominant circulating strain of influenza in many communities at this time. In addition, surveillance and clinical

Highlights:

- **H1N1 influenza A virus is the predominant circulating strain of influenza in many communities at this time**
- **For Ambulatory Care Settings and Emergency Departments, laboratory testing is only required for clinical management of hospitalized cases of ILI or for patients at high risk for complications**

data have shown that the majority of confirmed cases have experienced mild symptoms.

Health care providers in ambulatory care settings and emergency departments should therefore only submit laboratory specimens in cases where lab results are required for clinical management of hospitalized cases of influenza-like illness (ILI) or where patients are at high risk for complications from influenza (e.g., immunocompromised, pregnant, persons under the age of 2 years and over 65 years of age).

Note – Laboratory testing is not recommended to determine if treatment with antivirals is indicated. Treatment decisions should be based on clinical features only.

The following guidance documents have been revised to reflect these recommendations:

- *Clinical Guidelines for Management of Patients with ILI in Ambulatory Care Settings*
- *Clinical Guidelines for Management of Patients with ILI in Emergency Departments*

The updated guidance documents are available on the ministry H1N1 Flu Virus website in the section for Health Care Providers under “Emergency Departments” and “Ambulatory Care Settings” at: www.health.gov.on.ca/english/public/updates/archives/hu_09/provider/default.html

Health Care Provider Hotline

If you are a health care worker and have any questions or concerns on the Important Health Notices and related guidance documents, please call the Health Care Provider Hotline toll-free at 1-866-212-2272*.

Hours of Operation**:

Monday-Friday	0900hrs to 1600hrs
Saturday-Sunday	CLOSED**

*This hotline is intended to provide guidance and support to health care workers only and is not a service to provide general information to the public.

**Hours of Operation are subject to change. Please monitor future Important Health Notices for changes.

**On-call services are available for urgent issues, and can be reached through the Health Care Provider Hotline.

(original signed by)

Dr. David Williams
Acting Chief Medical Officer of Health

(original signed by)

Phil Graham
Interim Director, Emergency Management Unit